Related references
Note: Only part of the references are listed.The Nordic prescription databases as a resource for pharmacoepidemiological researcha literature review
B. Wettermark et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
The role of comorbidities on the uptake of systemic treatment and 3-year survival in older cancer patients
E. P. Stavrou et al.
ANNALS OF ONCOLOGY (2012)
A life-cycle approach to monitoring benefits and harms of medicines
Emily Banks et al.
MEDICAL JOURNAL OF AUSTRALIA (2012)
Two Hundred Years of Cancer Research
Vincent T. DeVita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Validation and application of a death proxy in adult cancer patients
Nicole M. Mealing et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Discontinuation of statin therapy in older people: does a cancer diagnosis make a difference? An observational cohort study using data linkage
Efty P. Stavrou et al.
BMJ OPEN (2012)
Updating and Validating the Charlson Comorbidity Index and Score for Risk Adjustment in Hospital Discharge Abstracts Using Data From 6 Countries
Hude Quan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2011)
Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia
A. I. Vitry et al.
INTERNAL MEDICINE JOURNAL (2011)
High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
Sebastian Schneeweiss et al.
EPIDEMIOLOGY (2009)
Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates
Elizabeth E. Roughead et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Flexible modeling of the cumulative effects of time-dependent exposures on the hazard
Marie-Pierre Sylvestre et al.
STATISTICS IN MEDICINE (2009)
Degree-of-spread artefact in the New South Wales Central Cancer Registry
Helen Barraclough et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH (2008)
NSAID Use in Individuals at Risk of Renal Adverse Events An Observational Study to Investigate Trends in Australian Veterans
Elizabeth E. Roughead et al.
DRUG SAFETY (2008)
Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia
Lisa M. Kalisch et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2008)
Patterns of analgesic and anti-inflammatory medicine use by Australian veterans
S. -A. Pearson et al.
INTERNAL MEDICINE JOURNAL (2007)
Trastuzumab and metastatic breast cancer: Trastuzumab use in Australia - Monitoring the effect of an expensive medicine access program
Sallie-Anne Pearson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pharmaceutical brand substitution in Australia - are there multiple switches per prescription?
Lisa M. Kalisch et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH (2007)
Improving medication safety: influence of a patient-specific prescriber feedback program on rate of medication reviews performed by Australian general medical practitioners
Elizabeth Roughead et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Potentially inappropriate prescribing among Australian veterans and war widows/widowers
E. E. Roughead et al.
INTERNAL MEDICINE JOURNAL (2007)
Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans
Elizabeth E. Roughead et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2007)
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: An Australian population-based analysis
D. Damianovich et al.
BRITISH JOURNAL OF CANCER (2007)
Adverse drug events resulting from patient errors in older adults
Terry S. Field et al.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2007)
Adapting the Rx-Risk-V for mortality prediction in outpatient populations
Michael L. Johnson et al.
MEDICAL CARE (2006)
A review of uses of health care utilization databases for epidemiologic research on therapeutics
S Schneeweiss et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cutting the cost of drug development?
MD Rawlins
NATURE REVIEWS DRUG DISCOVERY (2004)
Incidence and preventability of adverse drug events among older persons in the ambulatory setting
JH Gurwitz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
A cost-effectiveness approach to drug subsidy and pricing in Australia
DJ Birkett et al.
HEALTH AFFAIRS (2001)
Share Paper
